Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06492746 · ClinicalTrials.gov registry record · NA

Personal BP - CAI Study

A NA study of Blood Pressure, sponsored by Edwards Lifesciences.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
1
Study location

NCT06492746 is a NA study of Blood Pressure that is actively recruiting participants, run by Edwards Lifesciences. The registered enrollment target is 120 participants, below the 286-participant average among 101 other Blood Pressure trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06492746, a NA study of Blood Pressure, is actively recruiting participants, sponsored by Edwards Lifesciences.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

A single-center, prospective, observational pilot of the Cerebral Adaptive Index for assessing personalized blood pressure targets

Conditions Studied

Interventions

  • DEVICE HemoSphere Advanced Monitoring Platform with Acumen IQ sensor and Tissue Oximetry Monitoring

Study Locations (1)

Illinois

  • Northwestern University Hospital - Evanston

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2024-06-03
Est. Completion 2025-12
Phase NA

Sponsor

Edwards Lifesciences

57 total trials

What the Registry Record Tells You About NCT06492746

The ClinicalTrials.gov registry entry for NCT06492746 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 286-participant average among 101 other Blood Pressure trials with a reported enrollment target (58% lower). The listed sponsor is Edwards Lifesciences, which has 57 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Blood Pressure appearing as the primary indexed condition, and to 1 intervention - of which HemoSphere Advanced Monitoring Platform with Acumen IQ sensor and Tissue Oximetry Monitoring is the first listed.

NCT06492746 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT06492746 about?

NCT06492746 is a clinical study titled "Personal BP - CAI Study". A single-center, prospective, observational pilot of the Cerebral Adaptive Index for assessing personalized blood pressure targets

What is the current status of trial NCT06492746?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2024-06-03. Estimated completion is 2025-12.

What conditions does trial NCT06492746 study?

This clinical trial studies the following conditions: Blood Pressure.

What interventions are being tested in trial NCT06492746?

The interventions under investigation include: HemoSphere Advanced Monitoring Platform with Acumen IQ sensor and Tissue Oximetry Monitoring (DEVICE).

Who is sponsoring clinical trial NCT06492746?

This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06492746 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Blood Pressure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.